drugset / Trial / NCT07704645
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )
Timeline
- Start
- 2026-08
- Primary completion
- 2028-06
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | HRS-7058 | Unknown | — | — |
| Subject | SHR-1826 | Unknown | — | — |
| Subject | SHR-8068 | Monoclonal antibody | — | — |